TREE NEWS update: Novo Nordisk reported results from its Reimagine 5 trial, in which its CagriSema treatment achieved a 12.4% weight reduction. The company disclosed the headline efficacy figure for the obesity drug candidate in the study.
Novo Nordisk’s CagriSema Shows 12.4% Weight Loss in Reimagine 5 Trial
AI take
The headline number lands below the weight-loss bar set by the most potent injectables already on the market, which matters more for Novo's competitive positioning than for the mechanism itself. The disclosure is also thin: without tolerability, discontinuation or trial-population detail, the efficacy figure alone can't be read as a clean win or loss. Whether CagriSema's profile improves in the remaining readouts, and how payers weigh incremental efficacy against cost, is the open question.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
3m ago
Porsche Dealers Deny Cayenne Discounted to 618,000 Yuan
10m ago
Fed’s Goolsbee: Restoring Price Stability ‘Won’t Be Painless’
18m ago
Trump Urges Zelensky to Halt Strikes on Russian Refineries
20m ago
Oil slides: WTI drops 3.0% to $93.18, Brent falls 2.5% to $96.78
22m ago
ByteDance Unit Buys Beijing Olympic Park Plot for 2.613B Yuan
23m ago
UK Air Traffic Control Hit by Technical Fault, Flights Delayed in Scotland and Northern England